论文部分内容阅读
目的:探讨Med1/TRAP220和uPAR在非小细胞肺癌中表达的临床病理意义。方法:用免疫组织化学技术检测120例非小细胞肺癌组织中Med1/TRAP220和uPAR的表达,并分析其与患者临床病理指标的关系及其和预后的关系。结果:免疫组化结果显示在120例非小细胞肺癌中Med1/TRAP220的阳性表达率为53.3%,uPAR的阳性表达率为70%,癌旁正常肺组织uPAR阳性表达率为12.5%(15/120),Med1/TRAP220的阳性表达率为80%(96/120)。uPAR在肺癌中的阳性表达率显著高于癌旁正常肺组织(P<0.01),Med1/TRAP220在癌旁正常肺组织中的阳性表达率显著高于肺癌组织(P<0.01)。Med1/TRAP220和uPAR在肺癌中的表达与性别,年龄,肿瘤大小无关(P>0.05)。有淋巴结转移组uPAR的阳性表达率显著高于无淋巴结转移组(P<0.05),而无淋巴结转移组Med1/TRAP220的阳性表达率显著高于有淋巴结转移组(P<0.05)。uPAR的阳性表达率与非小细胞肺癌的临床分期无显著相关(P>0.05),而I-II期非小细胞肺癌组Med1/TRAP220的阳性表达率显著高于III-IV期组(P<0.05)。uPAR在肺鳞癌和腺癌中的表达率有显著差异(P<0.05),而Med1/TRAP220在肺鳞癌和腺癌中的表达率无显著差异(P>0.05)。uPAR阳性组生存率显著低于uPAR阴性组(P<0.05),而Med1/TRAP220阳性组生存率显著高于Med1/TRAP220阴性组(P<0.05)。Cox比例危险度模型显示uPAR阳性表达反映不良预后的危险性最大,风险度exp(β)为2.012(P<0.01),其次为肿瘤的TNM分期,风险度exp(β)为1.521,而Med1/TRAP220为预后有利因素,风险度exp(β)为0.386(P<0.01)。结论:Med1/TRAP220和uPAR联合应用在非小细胞肺癌预后预测中有重要意义。
Objective: To investigate the clinicopathological significance of the expression of Med1 / TRAP220 and uPAR in non-small cell lung cancer. Methods: The expressions of Med1 / TRAP220 and uPAR in 120 non-small cell lung cancer tissues were detected by immunohistochemical technique. The relationship between the expression of Med1 / TRAP220 and uPAR was analyzed with the clinicopathological parameters and prognosis. Results: The immunohistochemical results showed that the positive rate of Med1 / TRAP220 was 53.3%, the positive rate of uPAR was 70% and the rate of uPAR in normal lung tissues was 12.5% (15 / 120). The positive expression rate of Med1 / TRAP220 was 80% (96/120). The positive rate of uPAR expression in lung cancer was significantly higher than that in adjacent normal lung tissues (P <0.01). The positive expression rate of Med1 / TRAP220 in normal lung tissues was significantly higher than that in lung cancer tissues (P <0.01). The expression of Med1 / TRAP220 and uPAR in lung cancer was not related to gender, age, tumor size (P> 0.05). The positive expression rate of uPAR in lymph node metastasis group was significantly higher than that in non-lymph node metastasis group (P <0.05), while the positive expression rate of Med1 / TRAP220 in non-lymph node metastasis group was significantly higher than that in lymph node metastasis group (P <0.05). The positive expression rate of uPAR was not significantly correlated with the clinical stage of NSCLC (P> 0.05), but the positive rate of Med1 / TRAP220 in stage I-II non-small cell lung cancer was significantly higher than that in stage III-IV (P < 0.05). The expression of uPAR was significantly different between squamous cell carcinoma and adenocarcinoma (P <0.05), while the expression of Med1 / TRAP220 was not significantly different between squamous cell carcinoma and adenocarcinoma (P> 0.05). The survival rate of uPAR positive group was significantly lower than that of uPAR negative group (P <0.05), while the survival rate of Med1 / TRAP220 positive group was significantly higher than that of Med1 / TRAP220 negative group (P <0.05). Cox proportional hazard model showed that uPAR positive expression had the highest risk of adverse prognosis, the risk exp (β) was 2.012 (P <0.01), followed by TNM stage of the tumor, the risk exp (β) was 1.521, while the expression of Med1 / TRAP220 was a favorable prognostic factor with a risk exp (β) of 0.386 (P <0.01). Conclusion: The combination of Med1 / TRAP220 and uPAR is of great importance in predicting the prognosis of non-small cell lung cancer.